William Blair Investment Management LLC lifted its position in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 89.2% in the third quarter, HoldingsChannel.com reports. The firm owned 2,709,212 shares of the biotechnology company’s stock after purchasing an additional 1,277,616 shares during the period. William Blair Investment Management LLC’s holdings in Veracyte were worth $124,732,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Allworth Financial LP increased its position in shares of Veracyte by 81.4% during the third quarter. Allworth Financial LP now owns 1,533 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 688 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Veracyte by 7.8% in the third quarter. Russell Investments Group Ltd. now owns 97,813 shares of the biotechnology company’s stock worth $4,503,000 after acquiring an additional 7,088 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in Veracyte during the 3rd quarter valued at about $34,000. Fifth Third Bancorp lifted its position in Veracyte by 7.5% in the 3rd quarter. Fifth Third Bancorp now owns 55,232 shares of the biotechnology company’s stock valued at $2,543,000 after acquiring an additional 3,831 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its holdings in shares of Veracyte by 54.8% during the third quarter. Maryland State Retirement & Pension System now owns 17,964 shares of the biotechnology company’s stock valued at $827,000 after purchasing an additional 6,359 shares in the last quarter.
Analyst Upgrades and Downgrades
A number of research firms have commented on VCYT. Wolfe Research downgraded shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 6th. Stephens dropped their price target on shares of Veracyte from $55.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, November 11th. Zacks Research downgraded Veracyte from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Wall Street Zen cut shares of Veracyte from a “buy” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, Piper Sandler lowered their target price on Veracyte from $54.00 to $30.00 and set an “overweight” rating for the company in a research report on Tuesday, November 10th. Six analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Veracyte currently has a consensus rating of “Hold” and an average target price of $44.50.
Get Our Latest Stock Report on Veracyte
Veracyte Price Performance
VCYT stock opened at $24.33 on Monday. The firm’s 50-day moving average is $42.16 and its 200 day moving average is $42.44. Veracyte, Inc. has a 12 month low of $21.91 and a 12 month high of $60.91. The company has a market capitalization of $1.96 billion, a PE ratio of 15.70 and a beta of 1.98.
Veracyte (NASDAQ:VCYT – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. The company had revenue of $151.75 million during the quarter, compared to analysts’ expectations of $147.13 million. Veracyte had a return on equity of 8.99% and a net margin of 21.80%. The firm’s revenue was up 15.1% compared to the same quarter last year. During the same period last year, the business posted $0.51 earnings per share. Sell-side analysts forecast that Veracyte, Inc. will post 1.34 EPS for the current fiscal year.
Insider Transactions at Veracyte
In other Veracyte news, Director Muna Bhanji sold 1,864 shares of the firm’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $43.70, for a total value of $81,456.80. Following the sale, the director directly owned 40,854 shares of the company’s stock, valued at approximately $1,785,319.80. This trade represents a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Annie Mcguire sold 3,254 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $43.09, for a total value of $140,214.86. Following the sale, the executive vice president owned 131,160 shares of the company’s stock, valued at approximately $5,651,684.40. This trade represents a 2.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 62,609 shares of company stock valued at $2,858,904 over the last quarter. Company insiders own 1.60% of the company’s stock.
Veracyte Profile
Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.
See Also
- Five stocks we like better than Veracyte
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Free Report).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
